US Stock MarketDetailed Quotes
HCWB HCW Biologics
- 0.621
- +0.001+0.20%
Close Jul 5 16:00 ET
- 0.651
- +0.030+4.79%
Post 19:37 ET
23.50MMarket Cap-817P/E (TTM)
0.630High0.600Low5.70KVolume0.600Open0.620Pre Close3.51KTurnover0.03%Turnover RatioLossP/E (Static)37.82MShares2.32052wk High2.69P/B11.09MFloat Cap0.60052wk Low--Dividend TTM17.85MShs Float7.775Historical High--Div YieldTTM4.84%Amplitude0.600Historical Low0.616Avg Price1Lot Size
HCW Biologics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 0.94%-3.6M | -116.77%-22.51M | -2.78%-3.89M | -141.46%-5.59M | -249.16%-9.39M | -128.51%-3.64M | 5.37%-10.39M | -12.22%-3.79M | 54.78%-2.31M | -171.58%-2.69M |
| Net income from continuing operations | -47.28%-7.47M | -67.74%-24.99M | -97.10%-10.68M | -26.17%-4.94M | -22.61%-4.3M | -146.48%-5.07M | -15.85%-14.9M | -70.75%-5.42M | 4.41%-3.91M | -27.64%-3.51M |
| Operating gains losses | ---- | ---15.63K | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -18.52%243.5K | 58.14%1.14M | 5.13%274.55K | 68.84%277.45K | 90.09%284.33K | 109.30%298.85K | 32.06%717.85K | 143.02%261.16K | 34.20%164.33K | -3.42%149.58K |
| Other non cash items | -300.00%-418 | -179.99%-1.67K | -200.00%-626 | -200.00%-627 | -200.00%-627 | 0.00%209 | -92.61%2.09K | --626 | --627 | --627 |
| Change In working capital | 242.19%3.38M | -286.61%-4.64M | -12.89%1M | -201.72%-1.11M | -1,573.08%-5.52M | 899.48%986.71K | 70.96%2.49M | 252.36%1.15M | 194.75%1.09M | -76.49%374.97K |
| -Change in receivables | 283.03%631.87K | -292.72%-1.12M | -1,228.74%-825.68K | 66.74%-2.87K | -320.54%-454.48K | 139.28%164.97K | -112.03%-284.7K | 1.37%-62.14K | 56.90%-8.62K | -83.51%206.07K |
| -Change in prepaid assets | 66.02%302.64K | -294.04%-4.82M | 8.71%683.42K | -1,994.85%-201.19K | -1,233.74%-5.48M | -86.79%182.29K | 188.69%2.48M | 201.74%628.67K | 99.41%-9.6K | 217.06%483.54K |
| -Change in payables and accrued expense | 247.65%2.5M | 287.21%1.62M | 97.45%1.23M | -171.64%-820.12K | 278.66%494.25K | 167.10%718.68K | -77.85%418.21K | 951.96%621.19K | 133.74%1.14M | -136.50%-276.65K |
| -Change in other current liabilities | 28.63%-56.54K | -154.78%-326.74K | -114.00%-83.75K | -113.92%-82.5K | -113.84%-81.27K | -531.63%-79.23K | ---128.25K | ---39.14K | ---38.57K | ---38K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 0.94%-3.6M | -116.77%-22.51M | -2.78%-3.89M | -141.46%-5.59M | -249.16%-9.39M | -128.51%-3.64M | 5.37%-10.39M | -12.22%-3.79M | 54.78%-2.31M | -171.58%-2.69M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 56.82%-129.71K | -74.18%3.8M | -5,309.54%-3.72M | 37.52%9.37M | -11,959.46%-1.56M | -103.77%-300.39K | 142.00%14.71M | -187.35%-68.69K | 119.48%6.81M | -12.91K |
| Net PPE purchase and sale | 56.82%-129.71K | 39.63%-6.2M | -5,309.54%-3.72M | 93.80%-630.05K | -11,959.46%-1.56M | -1,175.30%-300.39K | -21,640.32%-10.28M | -246.00%-68.69K | -246,027.30%-10.17M | ---12.91K |
| Net investment purchase and sale | ---- | -59.97%10M | --0 | -41.12%10M | ---- | ---- | 171.44%24.98M | --0 | 148.57%16.98M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 56.82%-129.71K | -74.18%3.8M | -5,309.54%-3.72M | 37.52%9.37M | -11,959.46%-1.56M | -103.77%-300.39K | 142.00%14.71M | -187.35%-68.69K | 119.48%6.81M | ---12.91K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 222,022.78%4.22M | -100.23%-14.53K | 61.73%-15.25K | -100.14%-8.9K | 28.53%7.71K | -16.37%1.9K | -87.27%6.27M | -753.00%-39.85K | -87.43%6.3M | 100.74%6K |
| Net issuance payments of debt | --1.72M | -100.59%-38.27K | ---29.29K | ---- | ---- | --0 | --6.45M | --0 | ---- | ---- |
| Net common stock issuance | 131,528.62%2.5M | 50.46%23.74K | 140.82%14.04K | -94.98%84 | 28.53%7.71K | -16.37%1.9K | -99.97%15.78K | -4.44%5.83K | -100.00%1.67K | -36.61%6K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | 97.18%-190.55K | ---45.68K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 222,022.78%4.22M | -100.23%-14.53K | 61.73%-15.25K | -100.14%-8.9K | 28.53%7.71K | -16.37%1.9K | -87.27%6.27M | -753.00%-39.85K | -87.43%6.3M | 100.74%6K |
| Net cash flow | ||||||||||
| Beginning cash position | -83.90%3.6M | 90.32%22.33M | -57.21%11.22M | -51.69%7.45M | 1.50%18.39M | 90.32%22.33M | 38.73%11.73M | 73.38%26.22M | 205.30%15.42M | 164.25%18.12M |
| Current changes in cash | 112.42%488.98K | -276.78%-18.73M | -95.64%-7.63M | -65.09%3.77M | -305.70%-10.94M | -161.64%-3.94M | 223.55%10.6M | -14.83%-3.9M | 7.24%10.8M | -49.38%-2.7M |
| End cash Position | -77.79%4.08M | -83.90%3.6M | -83.90%3.6M | -57.21%11.22M | -51.69%7.45M | 1.50%18.39M | 90.32%22.33M | 90.32%22.33M | 73.38%26.22M | 205.30%15.42M |
| Free cash flow | 5.21%-3.73M | -38.99%-28.72M | -97.26%-7.61M | 50.18%-6.22M | -305.08%-10.95M | -143.77%-3.94M | -87.44%-20.66M | -13.59%-3.86M | -143.70%-12.48M | -172.88%-2.7M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg